CY1118001T1 - Νεες ctla4-ig προσκολλητινες - Google Patents
Νεες ctla4-ig προσκολλητινεςInfo
- Publication number
- CY1118001T1 CY1118001T1 CY20161100794T CY161100794T CY1118001T1 CY 1118001 T1 CY1118001 T1 CY 1118001T1 CY 20161100794 T CY20161100794 T CY 20161100794T CY 161100794 T CY161100794 T CY 161100794T CY 1118001 T1 CY1118001 T1 CY 1118001T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ctla4
- stickers
- new
- adhesins
- target
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30631110P | 2010-02-19 | 2010-02-19 | |
| US33480610P | 2010-05-14 | 2010-05-14 | |
| US41230910P | 2010-11-10 | 2010-11-10 | |
| PCT/US2011/025747 WO2011103584A2 (en) | 2010-02-19 | 2011-02-22 | Novel ctla4-ig immunoadhesins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118001T1 true CY1118001T1 (el) | 2017-05-17 |
Family
ID=44483626
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100794T CY1118001T1 (el) | 2010-02-19 | 2016-08-10 | Νεες ctla4-ig προσκολλητινες |
| CY20201100987T CY1124024T1 (el) | 2010-02-19 | 2020-10-20 | Νεες ctla4-ig ανοσοπροσκολλητινες |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100987T CY1124024T1 (el) | 2010-02-19 | 2020-10-20 | Νεες ctla4-ig ανοσοπροσκολλητινες |
Country Status (19)
| Country | Link |
|---|---|
| US (7) | US8329867B2 (https=) |
| EP (2) | EP2536745B1 (https=) |
| JP (1) | JP5705242B2 (https=) |
| KR (1) | KR101926663B1 (https=) |
| CN (3) | CN103038251B (https=) |
| AU (2) | AU2011217770B2 (https=) |
| CA (1) | CA2790487C (https=) |
| CY (2) | CY1118001T1 (https=) |
| DK (2) | DK2536745T3 (https=) |
| ES (2) | ES2586579T3 (https=) |
| HR (2) | HRP20160938T1 (https=) |
| HU (2) | HUE050768T2 (https=) |
| LT (2) | LT3053932T (https=) |
| PL (2) | PL3053932T3 (https=) |
| PT (1) | PT3053932T (https=) |
| RS (1) | RS61136B1 (https=) |
| SI (2) | SI2536745T1 (https=) |
| SM (2) | SMT202000572T1 (https=) |
| WO (1) | WO2011103584A2 (https=) |
Families Citing this family (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| ES2892925T3 (es) | 2006-03-31 | 2022-02-07 | Chugai Pharmaceutical Co Ltd | Métodos para controlar la farmacocinética en sangre de anticuerpos |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| ES2751549T3 (es) | 2009-11-30 | 2020-04-01 | Janssen Biotech Inc | Mutantes de anticuerpos Fc con funciones efectoras ablacionadas |
| US10053513B2 (en) * | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| PL3053932T3 (pl) * | 2010-02-19 | 2021-03-08 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| CN106432474A (zh) * | 2010-03-12 | 2017-02-22 | 艾伯维生物医疗股份有限公司 | Ctla4蛋白和其用途 |
| TWI667346B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| TWI812066B (zh) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| CN112812184A (zh) | 2011-02-25 | 2021-05-18 | 中外制药株式会社 | FcγRIIb特异性Fc抗体 |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| JP6124800B2 (ja) | 2011-11-30 | 2017-05-10 | 中外製薬株式会社 | 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬 |
| KR101536151B1 (ko) * | 2012-01-31 | 2015-07-14 | 서울대학교산학협력단 | 새로운 ＣＴＬＡ-４ＩｇＧ 융합 단백질 |
| JP6226752B2 (ja) | 2012-02-09 | 2017-11-08 | 中外製薬株式会社 | 抗体のＦｃ領域改変体 |
| US9758566B2 (en) * | 2012-03-29 | 2017-09-12 | The General Hospital Corporation | Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4) |
| JP6228971B2 (ja) | 2012-05-11 | 2017-11-08 | メディミューン，エルエルシー | Ｃｔｌａ−４バリアント |
| US9695244B2 (en) | 2012-06-01 | 2017-07-04 | Momenta Pharmaceuticals, Inc. | Methods related to denosumab |
| US20150210753A1 (en) | 2012-07-26 | 2015-07-30 | Momenta Pharmaceuticals, Inc. | Glycoproteins with anti-inflammatory properties |
| TW202237660A (zh) | 2012-08-24 | 2022-10-01 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| US10450361B2 (en) | 2013-03-15 | 2019-10-22 | Momenta Pharmaceuticals, Inc. | Methods related to CTLA4-Fc fusion proteins |
| AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| WO2014186310A1 (en) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| EP3017048A4 (en) * | 2013-07-01 | 2017-05-17 | University of Maryland, College Park | Fc coupled compositions and methods of their use |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| EP3058084A4 (en) | 2013-10-16 | 2017-07-05 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| PL3110434T3 (pl) * | 2014-02-24 | 2019-01-31 | Takeda Gmbh | Białka fuzyjne uti |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| KR102524920B1 (ko) | 2014-07-22 | 2023-04-25 | 아폴로믹스 인코포레이티드 | 항-pd-1 항체 |
| US10435470B2 (en) | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| UA123624C2 (uk) * | 2014-09-03 | 2021-05-05 | Бьорінґер Інґельхайм Інтернаціональ Ґмбх | Сполука, специфічна до іл-23а та фнп-альфа, та її застосування |
| MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| JP6668345B2 (ja) | 2014-11-21 | 2020-03-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 修飾された重鎖定常領域を含む抗体 |
| CN107207594B (zh) | 2014-12-23 | 2019-05-07 | 百时美施贵宝公司 | 针对tigit的抗体 |
| TWI691512B (zh) * | 2015-02-20 | 2020-04-21 | 日商橘生藥品工業股份有限公司 | Ｆｃ融合高親和性ＩｇＥ受體α鏈 |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| CN107667173A (zh) | 2015-05-06 | 2018-02-06 | 斯尼普技术有限公司 | 改变微生物种群和改善微生物群 |
| FR3035879B1 (fr) * | 2015-05-07 | 2025-02-28 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
| TN2019000101A1 (en) | 2015-05-29 | 2020-07-15 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof. |
| AU2016285920A1 (en) | 2015-06-29 | 2018-02-01 | Bristol-Myers Squibb Company | Antibodies to CD40 with enhanced agonist activity |
| IL256665B2 (en) * | 2015-07-23 | 2023-10-01 | Boehringer Ingelheim Int | IL-23A Targeting Compound and B-Cell Activating Factor Nucleic Acids Encoding Them and Use of Products Containing Them |
| EP3370733B1 (en) | 2015-11-02 | 2021-07-14 | Board of Regents, The University of Texas System | Methods of cd40 activation and immune checkpoint blockade |
| US20190038713A1 (en) | 2015-11-07 | 2019-02-07 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| EP3192805A1 (en) * | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
| ES2985566T3 (es) | 2016-03-04 | 2024-11-06 | Univ Rockefeller | Anticuerpos contra CD40 con actividad agonista mejorada |
| KR20230038311A (ko) | 2016-03-04 | 2023-03-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
| WO2017160599A1 (en) | 2016-03-14 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of cd300b antagonists to treat sepsis and septic shock |
| US11046782B2 (en) | 2016-03-30 | 2021-06-29 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination |
| DK3449017T3 (da) | 2016-04-29 | 2022-03-14 | Univ Texas | Målrettet måling af transkriptionel aktivitet vedrørende hormonreceptorer |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| US10864203B2 (en) | 2016-07-05 | 2020-12-15 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
| PT3500299T (pt) | 2016-08-19 | 2024-02-21 | Beigene Switzerland Gmbh | Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro |
| JP7542946B2 (ja) | 2016-09-27 | 2024-09-02 | ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム | マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法 |
| CN110072540B (zh) | 2016-10-12 | 2023-06-02 | 得克萨斯州大学系统董事会 | 用于tusc2免疫治疗的方法和组合物 |
| EP3538112B1 (en) | 2016-11-09 | 2026-02-25 | Musc Foundation for Research Development | Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy |
| MA46852A (fr) | 2016-11-17 | 2019-09-25 | Univ Texas | Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20 |
| WO2018111902A1 (en) | 2016-12-12 | 2018-06-21 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| WO2018156973A1 (en) | 2017-02-24 | 2018-08-30 | Board Of Regents, The University Of Texas System | Assay for detection of early stage pancreatic cancer |
| WO2018161092A1 (en) | 2017-03-03 | 2018-09-07 | New York University | Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins |
| EP3596114A2 (en) * | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| IL270596B2 (en) | 2017-05-25 | 2026-01-01 | Bristol Myers Squibb Co | Antibodies containing heavy constant regions are adapted for use in cancer therapy |
| KR20200015717A (ko) | 2017-06-09 | 2020-02-12 | 프로비던스 헬스 앤드 서비시즈 - 오레곤 | 암 치료를 위한 인간 종양 반응성 t 세포의 확인을 위한 cd39 및 cd103의 활용 |
| TW202515616A (zh) | 2017-06-26 | 2025-04-16 | 英屬開曼群島商百濟神州有限公司 | 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途 |
| KR102631281B1 (ko) * | 2017-08-10 | 2024-01-30 | 그리폴스 다이어그노스틱 솔루션즈 인크. | 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트 |
| KR102813968B1 (ko) * | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| CN119930795A (zh) | 2017-10-12 | 2025-05-06 | 得克萨斯大学体系董事会 | 用于免疫疗法的t细胞受体 |
| SMT202600062T1 (it) | 2017-10-18 | 2026-03-09 | Alpine Immune Sciences Inc | Proteine immunomodulatrici del ligando di icos variante e composizioni e metodi correlati |
| KR20200085780A (ko) | 2017-11-07 | 2020-07-15 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 암의 치료에서 car-t 또는 car-nk 세포를 사용한 lilrb4 표적화 |
| CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
| CA3084821A1 (en) | 2017-12-15 | 2019-06-20 | Board Of Regents, The University Of Texas System | Methods and compositions for treating cancer using exosomes-associated gene editing |
| CN111788227B (zh) | 2017-12-27 | 2025-02-25 | 百时美施贵宝公司 | 抗cd40抗体及其用途 |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| WO2019173223A1 (en) * | 2018-03-05 | 2019-09-12 | New York University | Induction and enhancement of antitumor immunity involving sindbis virus vectors expressing immune checkpoint proteins |
| US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
| EP3768698B1 (en) | 2018-03-19 | 2025-02-12 | MultiVir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| AU2019246043B2 (en) | 2018-03-25 | 2024-07-04 | Snipr Biome Aps. | Treating and preventing microbial infections |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| SG11202009498RA (en) | 2018-03-27 | 2020-10-29 | Univ Texas | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations |
| BR112020023860A2 (pt) * | 2018-05-25 | 2021-04-13 | Dr. Reddy's Laboratories Ltd. | Formulação estável de proteína de fusão, e, métodos para obter uma formulação estável e para aumentar a estabilidade de proteína de fusão |
| KR20210124179A (ko) * | 2018-11-02 | 2021-10-14 | 베이징 브이디제이바이오 컴퍼니 리미티드 | 변형된 ctla4 및 이의 사용 방법 |
| EP3883955A1 (en) | 2018-11-19 | 2021-09-29 | Board of Regents, The University of Texas System | A modular, polycistronic vector for car and tcr transduction |
| WO2020113029A2 (en) | 2018-11-28 | 2020-06-04 | Board Of Regents, The University Of Texas System | Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment |
| EP3887397A1 (en) | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| MX2021006393A (es) | 2018-11-29 | 2021-10-13 | Univ Texas | Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas. |
| WO2020113141A2 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| US12492380B2 (en) | 2019-05-09 | 2025-12-09 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of hepatocytes |
| JP2022532766A (ja) | 2019-05-17 | 2022-07-19 | キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド | 家族性腺腫性ポリポーシスを処置するための方法 |
| AU2020300002A1 (en) | 2019-07-01 | 2022-02-24 | Tonix Pharma Limited | Anti-CD154 antibodies and uses thereof |
| CN114599389A (zh) * | 2019-08-22 | 2022-06-07 | 奇达拉治疗公司 | 变体fc结构域及其用途 |
| PE20221906A1 (es) | 2019-09-18 | 2022-12-23 | Genentech Inc | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso |
| EP3795583A1 (en) * | 2019-09-19 | 2021-03-24 | Ecole Polytechnique Federale de Lausanne (EPFL) | Il10/fc fusion proteins useful as enhancers of immunotherapies |
| US20220380765A1 (en) | 2019-11-02 | 2022-12-01 | Board Of Regents, The University Of Texas System | Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| WO2021141977A1 (en) | 2020-01-07 | 2021-07-15 | Board Of Regents, The University Of Texas System | Improved human methyl thioadenosine/adenosine depleting enzyme variants for cancer therapy |
| CA3167288A1 (en) | 2020-01-10 | 2021-07-15 | Modernatx, Inc. | Methods of making tolerogenic dendritic cells |
| KR20220133238A (ko) | 2020-01-29 | 2022-10-04 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Nrg1 융합체가 있는 암의 치료를 위한 포지오티닙의 용도 |
| US20230112470A1 (en) | 2020-01-29 | 2023-04-13 | Board Of Regents, The University Of Texas System | Use of egfr/her2 tyrosine kinase inhibitors and/or her2/her3 antibodies for the treatment of cancers with nrg1 fusions |
| WO2021155267A2 (en) | 2020-01-30 | 2021-08-05 | Modernatx, Inc. | Mrnas encoding metabolic reprogramming polypeptides and uses thereof |
| WO2021167908A1 (en) | 2020-02-17 | 2021-08-26 | Board Of Regents, The University Of Texas System | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
| EP4142792A4 (en) | 2020-05-01 | 2024-11-27 | Kashiv Biosciences, LLC | An improved process of purification of protein |
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| AU2021275239A1 (en) | 2020-05-21 | 2022-12-15 | Board Of Regents, The University Of Texas System | T cell receptors with VGLL1 specificity and uses thereof |
| WO2021247836A1 (en) | 2020-06-03 | 2021-12-09 | Board Of Regents, The University Of Texas System | Methods for targeting shp-2 to overcome resistance |
| CA3201499A1 (en) | 2020-11-13 | 2022-05-19 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| WO2022115611A1 (en) | 2020-11-25 | 2022-06-02 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
| US20240059781A1 (en) | 2021-01-06 | 2024-02-22 | Tonix Pharma Limited | Methods of inducing immune tolerance with modified anti-cd154 antibodies |
| JP2024503480A (ja) | 2021-01-19 | 2024-01-25 | ウィリアム マーシュ ライス ユニバーシティ | ポリペプチドの骨特異的送達法 |
| WO2022192536A1 (en) * | 2021-03-11 | 2022-09-15 | The Methodist Hospital | Methods and compositions for treatment of disease |
| CA3218590A1 (en) | 2021-06-07 | 2022-12-15 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
| JP2024520805A (ja) | 2021-06-11 | 2024-05-24 | セージ セラピューティクス， インコーポレイテッド | アルツハイマー病の治療のための神経活性ステロイド |
| US20250114452A1 (en) | 2021-08-04 | 2025-04-10 | The Regents Of The University Of Colorado, A Body Corporate | Lat activating chimeric antigen receptor t cells and methods of use thereof |
| CN118369419A (zh) | 2021-10-05 | 2024-07-19 | 赛托维亚治疗有限责任公司 | 自然杀伤细胞及其使用方法 |
| KR20240099161A (ko) | 2021-10-20 | 2024-06-28 | 다케다 야쿠힌 고교 가부시키가이샤 | Bcma를 표적화하는 조성물 및 이의 사용 방법 |
| US20240409934A1 (en) | 2021-10-25 | 2024-12-12 | Board Of Regents, The University Of Texas System | Foxo1-targeted therapy for the treatment of cancer |
| US20250011388A1 (en) * | 2021-10-28 | 2025-01-09 | Monash University | Variant ctla4 proteins |
| US20250059230A1 (en) * | 2021-12-17 | 2025-02-20 | Kashiv Biosciences, Llc | An improved method for separation of low molecular weight proteins |
| EP4514382A1 (en) | 2022-04-28 | 2025-03-05 | Musc Foundation for Research Development | Chimeric antigen receptor modified regulatory t cells for treating cancer |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| AU2023367039A1 (en) | 2022-10-25 | 2025-05-15 | Ablexis, Llc | Anti-cd3 antibodies |
| WO2024107731A2 (en) | 2022-11-14 | 2024-05-23 | Ablexis, Llc | Anti-pd-l1 antibodies |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| WO2024212152A1 (en) * | 2023-04-13 | 2024-10-17 | Adagene Pte. Ltd. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2025248134A1 (en) | 2024-05-31 | 2025-12-04 | Tonix Pharma Limited | Treatment methods comprising administration of modified cd154 antibodies |
| WO2026064599A1 (en) | 2024-09-19 | 2026-03-26 | Zenas Biopharma, Inc. | Stable formulations for ctla4-ig fusion proteins and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1372696T1 (sl) * | 2000-07-03 | 2008-12-31 | Bristol Myers Squibb Co | Metoda za zdravljenje revmatskih bolezni z uporabo topne molekule ctla4 |
| AU2002243905B2 (en) * | 2001-01-26 | 2007-11-08 | Emory University | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| CN1443850A (zh) * | 2002-03-08 | 2003-09-24 | 重庆立丹(集团)药业科技开发有限公司 | 重组人ctla4胞外区蛋白的制备方法及其所得产品和用途 |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CN101519451B (zh) * | 2005-04-05 | 2011-05-25 | 上海中信国健药业股份有限公司 | 重组人sCTLA4-Ig融合蛋白基因及其药物组合物 |
| BRPI0608144A2 (pt) * | 2005-04-06 | 2009-11-17 | Bristol Myers Squibb Co | uso de uma molécula mutante de ctla4 |
| GB0620934D0 (en) | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
| CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| AU2008319053B2 (en) * | 2007-11-01 | 2012-04-26 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
| RU2529951C2 (ru) * | 2007-12-26 | 2014-10-10 | Ксенкор, Инк. | ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn |
| US8163551B2 (en) | 2008-05-02 | 2012-04-24 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| PL3053932T3 (pl) * | 2010-02-19 | 2021-03-08 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| CN106432474A (zh) * | 2010-03-12 | 2017-02-22 | 艾伯维生物医疗股份有限公司 | Ctla4蛋白和其用途 |
| KR102185854B1 (ko) | 2017-09-09 | 2020-12-02 | 애플 인크. | 생체측정 인증의 구현 |
-
2011
- 2011-02-22 PL PL15198516T patent/PL3053932T3/pl unknown
- 2011-02-22 PT PT151985165T patent/PT3053932T/pt unknown
- 2011-02-22 ES ES11727563.6T patent/ES2586579T3/es active Active
- 2011-02-22 EP EP11727563.6A patent/EP2536745B1/en active Active
- 2011-02-22 CA CA2790487A patent/CA2790487C/en active Active
- 2011-02-22 DK DK11727563.6T patent/DK2536745T3/en active
- 2011-02-22 DK DK15198516.5T patent/DK3053932T3/da active
- 2011-02-22 SI SI201130917A patent/SI2536745T1/sl unknown
- 2011-02-22 CN CN201180019721.1A patent/CN103038251B/zh active Active
- 2011-02-22 EP EP15198516.5A patent/EP3053932B1/en active Active
- 2011-02-22 WO PCT/US2011/025747 patent/WO2011103584A2/en not_active Ceased
- 2011-02-22 PL PL11727563T patent/PL2536745T3/pl unknown
- 2011-02-22 HU HUE15198516A patent/HUE050768T2/hu unknown
- 2011-02-22 HU HUE11727563A patent/HUE030100T2/en unknown
- 2011-02-22 LT LTEP15198516.5T patent/LT3053932T/lt unknown
- 2011-02-22 CN CN201610569505.9A patent/CN106432473B/zh active Active
- 2011-02-22 CN CN202110326502.3A patent/CN113372451B/zh active Active
- 2011-02-22 LT LTEP11727563.6T patent/LT2536745T/lt unknown
- 2011-02-22 KR KR1020127024362A patent/KR101926663B1/ko active Active
- 2011-02-22 JP JP2012554096A patent/JP5705242B2/ja active Active
- 2011-02-22 AU AU2011217770A patent/AU2011217770B2/en active Active
- 2011-02-22 RS RS20201231A patent/RS61136B1/sr unknown
- 2011-02-22 HR HRP20160938TT patent/HRP20160938T1/hr unknown
- 2011-02-22 US US13/032,491 patent/US8329867B2/en active Active
- 2011-02-22 SI SI201131924T patent/SI3053932T1/sl unknown
- 2011-02-22 ES ES15198516T patent/ES2826894T3/es active Active
- 2011-02-22 SM SM20200572T patent/SMT202000572T1/it unknown
-
2012
- 2012-12-10 US US13/710,305 patent/US8629113B2/en active Active
-
2013
- 2013-12-27 US US14/142,705 patent/US9371397B2/en active Active
-
2016
- 2016-05-03 AU AU2016202816A patent/AU2016202816B2/en active Active
- 2016-05-19 US US15/159,667 patent/US10155800B2/en active Active
- 2016-08-10 CY CY20161100794T patent/CY1118001T1/el unknown
- 2016-08-25 SM SM201600289T patent/SMT201600289B/it unknown
-
2018
- 2018-11-13 US US16/189,917 patent/US11352412B2/en active Active
-
2020
- 2020-10-08 HR HRP20201614TT patent/HRP20201614T1/hr unknown
- 2020-10-20 CY CY20201100987T patent/CY1124024T1/el unknown
-
2021
- 2021-04-15 US US17/231,848 patent/US11254727B2/en active Active
-
2022
- 2022-05-04 US US17/736,917 patent/US12486311B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118001T1 (el) | Νεες ctla4-ig προσκολλητινες | |
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| CY1120374T1 (el) | Ενεργοποιητες κινασων πυρουβικου για χρηση σε θεραπεια | |
| CY1119518T1 (el) | Τροποποιημενα αντιγονα φυματιωσης | |
| CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
| CL2012003385A1 (es) | Tratamiento para la incontinencia. | |
| CL2011000482S1 (es) | Aplicador para cuidado oral. | |
| UY34772A (es) | ?una formulación de fármaco de liberación retardada?. | |
| CL2012002979A1 (es) | Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona. | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| UY34165A (es) | ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?. | |
| UY34782A (es) | Anticuerpos humanos para fel d1 y métodos para usarlos. | |
| CR20150048A (es) | Anticuerpos e inmunoconjugados anti-cd22 | |
| GT201400063A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| GEAP202114132A (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| UY35210A (es) | Inhibidores de autotaxina | |
| UY34885A (es) | Proteínas de unión anti-mesotelina | |
| CY1117163T1 (el) | Ιμιδαζοπυριδαζινες ως αναστολεις κινασης ακτ | |
| CY1121696T1 (el) | Φαρμακευτικη συνθεση παρατεταμενης απελευθερωσης της τριμεταζιδινης | |
| CO7151478A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 | |
| MX383754B (es) | Composiciones para usarse en el tratamiento de la intolerancia al gluten y padecimientos relacionados. | |
| BR112014012945A2 (pt) | sistemas, dispositivos e métodos para acionar um modulador interferométrico analógico | |
| UY34286A (es) | Diagnóstico de vacuna mejorado | |
| UY4152Q (es) | Batería | |
| CY1120545T1 (el) | Συνθεση για τη θεραπεια της διαταραχης μειωμενης σεξουαλικης επιθυμιας |